Gilead Sciences
GILD
Delayed Nasdaq - 11/16 10:00:00 pm
69.2USD
-0.83%
Prev.69.7800
Open69.4500
High69.7000
Low68.9300
Volume9 249 339
Financials
Sales 2018 21 825 M
EBIT 2018 11 789 M
R. net 2018 7 221 M
Debt 2018 9 502 M
Rend. 2018 3,29%
P/E ratio 2018 12,55
P/E ratio 2019 12,17
EV / Sales 2018 4,54x
EV / Sales 2019 4,53x
Capitalization 89 518 M
Company
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need.The firm offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey,...
Sector :
Bio Therapeutic Drugs
Calendar :
2018-11-27 Presentation
Trading Rating :
Investor Rating :
Latest news
11/12GILEAD SCIENCES : to Present at the Evercore ISI HealthCONx Conference on Tuesday, November 27
BU
11/12GILEAD SCIENCES : Announces Positive Phase 2 Results for GS-9674 in Primary Sclerosing Cholangitis at the Liver Meeting 2018
AQ
11/12GILEAD SCIENCES : Presents Data from Nonalcoholic Steatohepatitis Development Program for Advanced Fibrosis at the Liver Meeting 2018
AQ
11/12GILEAD SCIENCES : Presents Latest Data from Viral Hepatitis Research Programs at the Liver Meeting 2018
AQ
11/09GILEAD SCIENCES : Presents Latest Data from Viral Hepatitis Research Programs at The Liver Meeting® 2018
BU
11/09GILEAD SCIENCES : Presents Data From Nonalcoholic Steatohepatitis (NASH) Development Program for Advanced Fibrosis at The Liver Meeting® 2018
BU
11/09GILEAD SCIENCES : Announces Positive Phase 2 Results for GS-9674 in Primary Sclerosing Cholangitis (PSC) at The Liver Meeting® 2018
BU
11/06GILEAD SCIENCES : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
Technical analysis trends
Short TermMid-TermLong Term
TrendBearishNeutralNeutral
Resistance72,579,085,5
Spread/Res.-4,6%-12%-19%
Spread/Supp.2,8%2,8%5,8%
Support67,367,365,4